Engineering effector immune cells to express chemokine receptors that match tumor-derived chemokines has been shown to increase their chemotaxis and to improve antitumor efficacy in preclinical models.
First-pass extracted concept
chemokine receptor engineering for engineered immune cell trafficking
Candidate: concept label1 source documents5 linked claims
Live refresh every 5sNext refresh in 5s
Evidence Snippets
Supporting Sources
Linked Claims
Chemokine receptor engineering can provide benefits beyond migration, including tumor microenvironment remodeling and metabolic rewiring of engineered cells.
Engineering effector immune cells with chemokine receptors matched to tumor-derived chemokines increases chemotaxis and improves antitumor efficacy in preclinical models.
The effectiveness of chemokine receptor engineering is limited by the tumor-specific and heterogeneous chemokine milieu.
Natural and synthetic GPCR engineering are promising approaches to enhance immune cell trafficking, persistence, and efficacy.
CAR cellular therapies have limited efficacy against solid tumors in part because effector cells traffic inefficiently to tumors.